tradingkey.logo

Illumina Inc

ILMN

90.250USD

+3.320+3.82%
Fechamento 06/16, 16:00ETCotações atrasadas em 15 min
14.35BValor de mercado
PerdaP/L TTM

Illumina Inc

90.250

+3.320+3.82%
Mais detalhes de Illumina Inc Empresa
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Informações da empresa
Código da empresaILMN
Nome da EmpresaIllumina Inc
Data de listagemJun 28, 2000
Fundado em2000
CEOMr. Jacob Thaysen, Ph.D.
Número de funcionários8970
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 28
Endereço5200 Illumina Way
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92122
Telefone18582024500
Sitehttps://www.illumina.com
Código da empresaILMN
Data de listagemJun 28, 2000
Fundado em2000
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.94K
+98.06%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+20.59%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+21.92%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+23.09%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
19.25K
+60.86%
Mr. Scott Davies
Mr. Scott Davies
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
18.93K
+58.70%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
17.13K
-31.74%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
+29.88%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Director
Independent Director
15.19K
+21.71%
Ms. Susan E. (Sue) Siegel
Ms. Susan E. (Sue) Siegel
Independent Director
Independent Director
14.46K
+35.38%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.94K
+98.06%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+20.59%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+21.92%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+23.09%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
19.25K
+60.86%
Mr. Scott Davies
Mr. Scott Davies
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
18.93K
+58.70%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
3.15B
72.16%
Services and Other revenue
716.00M
16.38%
Instruments
501.00M
11.46%
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.29B
52.33%
Europe
1.19B
27.10%
Asia, Middle East, and Africa
438.00M
10.02%
Greater China
308.00M
7.04%
Americas
153.00M
3.50%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
3.15B
72.16%
Services and Other revenue
716.00M
16.38%
Instruments
501.00M
11.46%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital World Investors
11.94%
The Vanguard Group, Inc.
10.29%
BlackRock Institutional Trust Company, N.A.
8.85%
Capital Research Global Investors
5.46%
State Street Global Advisors (US)
3.70%
Other
59.76%
Investidores
Investidores
Proporção
Capital World Investors
11.94%
The Vanguard Group, Inc.
10.29%
BlackRock Institutional Trust Company, N.A.
8.85%
Capital Research Global Investors
5.46%
State Street Global Advisors (US)
3.70%
Other
59.76%
Tipos de investidores
Investidores
Proporção
Investment Advisor
52.04%
Investment Advisor/Hedge Fund
36.71%
Hedge Fund
10.36%
Pension Fund
2.57%
Research Firm
2.52%
Bank and Trust
1.81%
Sovereign Wealth Fund
1.21%
Individual Investor
0.19%
Insurance Company
0.09%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
2030
169.86M
107.33%
-23.09M
2024Q4
2074
166.23M
104.94%
-15.71M
2024Q3
2038
151.41M
95.06%
-11.30M
2024Q2
2033
149.41M
93.80%
-18.06M
2024Q1
2096
153.02M
96.09%
-8.97M
2023Q4
2134
150.48M
94.76%
-5.28M
2023Q3
2162
152.18M
96.14%
-14.52M
2023Q2
2203
154.10M
97.47%
-5.40M
2023Q1
2219
149.37M
94.55%
-9.34M
2022Q4
2225
149.29M
94.92%
-10.46M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
18.03M
11.38%
+1.21M
+7.22%
Dec 31, 2024
The Vanguard Group, Inc.
15.74M
9.94%
-197.96K
-1.24%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.03M
8.86%
+262.47K
+1.91%
Dec 31, 2024
Capital Research Global Investors
8.66M
5.47%
+1.09K
+0.01%
Feb 28, 2025
State Street Global Advisors (US)
5.79M
3.66%
+185.73K
+3.31%
Dec 31, 2024
WCM Investment Management
4.13M
2.61%
+867.67K
+26.60%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
4.21M
2.66%
-132.58K
-3.05%
Dec 31, 2024
Corvex Management LP
1.70M
1.07%
-580.64K
-25.46%
Dec 31, 2024
Baillie Gifford & Co.
3.02M
1.91%
-604.62K
-16.69%
Dec 31, 2024
Brown Advisory
1.91M
1.21%
+1.91M
+54.22K%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Invesco Biotechnology & Genome ETF
4.57%
Global X Genomics & Biotechnology ETF
4%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.84%
First Trust NYSE Arca Biotechnology Index Fund
3.37%
VanEck Biotech ETF
2.86%
ARK Genomic Revolution ETF
1.8%
ROBO Global Healthcare Technology & Innovation ETF
1.78%
Alger Russell Innovation ETF
1.77%
First Trust Nasdaq AI and Robotics ETF
1.69%
Invesco Raymond James SB-1 Equity ETF
1.68%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção4.57%
Global X Genomics & Biotechnology ETF
Proporção4%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção3.84%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.37%
VanEck Biotech ETF
Proporção2.86%
ARK Genomic Revolution ETF
Proporção1.8%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.78%
Alger Russell Innovation ETF
Proporção1.77%
First Trust Nasdaq AI and Robotics ETF
Proporção1.69%
Invesco Raymond James SB-1 Equity ETF
Proporção1.68%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI